Probing method for identifying antibodies specific for selected antigens
AssigneeThe Dow Chemical Company
InventorsPeter S. Mezes, Brian Gourlie, Mark W. Rixon, W. H. Kerr Anderson
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Dow Chemical Company
InventorsPeter S. Mezes, Brian Gourlie, Mark W. Rixon, W. H. Kerr Anderson
Estimating the term…
This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal VH and VL sequences which mediate TAG-72 binding and (2) human CH and CL regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human CH and CL antibody domains. The nucleotide and amino acid sequences of VHαTAG VH, CC46 VH, CC49VH, CC83 VH, and CC92 VH, and CC49VL, CC83 VL, and CC92 VL idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.
A process for finding at least one murine VH-encoding polynucleotide encoding at least the heavy chain variable region (VH) of an antibody having binding specificity for TAG-72, the VH-encoding segment of said VH-encoding polynucleotide having a nucleotide sequence which is at least 80% homologous to the nucleotide sequence of the VHαTAG germline gene (SEQ ID NO:1), and said VH-encoding polynucleotide being a productively rearranged or mutated productively rearranged variant of the VHαTAG germline gene, said process comprising the steps of:
Dependencies are inferred from the claim text.